One avocado a day cut harmful LDL particle counts

Avocados have previously been shown to improve standard blood lipid profiles, but a standard cholesterol panel only tells part of the story. Cardiovascular risk research increasingly focuses on lipoprotein particles — the actual carriers of cholesterol in the blood — because the number and type of particles can matter beyond the cholesterol total. Whether a simple dietary addition like a daily avocado changes these particle-level measures has been unclear. This study set out to answer exactly that: does incorporating one avocado a day shift the concentrations of lipoprotein particles and their subclasses in people with abdominal obesity, a group at elevated cardiometabolic risk?

This was an ancillary study of the Habitual Diet and Avocado Trial, a multicentre, parallel-arm, 26-week randomised controlled trial in free-living adults with abdominal obesity. One group was provided with 1 avocado per day to add to their diet, while the comparison group was instructed to simply continue their habitual diet without supplemental avocados. Fasting plasma samples taken at baseline and at 26 weeks were analysed by nuclear magnetic resonance spectroscopy to measure lipoprotein particles and subclasses, which were exploratory outcomes. The analytical sample included 786 participants — 74% female, average age 51, average body mass index 32.9 — split between 389 in the avocado group and 397 in the habitual diet group.

The avocado group showed a reduction in total LDL particle concentration compared with the habitual diet group, with a mean difference of -49.1 nmol/L (95% CI -83.6 to -14.5, P = .005) over the 26 weeks. That was the extent of the effect: no between-group differences were observed for LDL particle size or LDL subclasses, for triglyceride-rich lipoprotein particles, for high-density lipoprotein particles, or for apolipoproteins A or B. In other words, the daily avocado moved one atherogenic particle measure while leaving the rest of the lipoprotein landscape unchanged. The authors conclude the intervention reduced atherogenic LDL particle concentration without affecting other particles and subclasses.

The finding extends earlier evidence that avocado intake improves blood lipids by adding particle-level detail from a large randomised trial rather than a small feeding study. It also complicates the picture: ApoB, which reflects the total number of atherogenic particles and is a marker many lipid researchers prioritise, did not differ between groups, which sits somewhat awkwardly alongside the drop in total LDL particle concentration. Because the particle measures were exploratory outcomes of an ancillary analysis, they should be read as hypothesis-generating rather than definitive. The key open question is whether a change of this size in one marker translates into any difference in actual cardiovascular events.

This is a reason to think that a daily avocado, added to an otherwise unchanged diet, can nudge at least one atherogenic blood marker in a favourable direction over half a year — in a population with abdominal obesity, without any prescribed calorie restriction. It is not a reason to view avocados as a treatment for high cholesterol: the effect was confined to a single measure, other markers including ApoB were untouched, and no health outcomes were assessed. For readers interested in their lipid numbers, the study is a useful illustration that food-level changes can register at the particle level, even if modestly.